8-K: Penumbra Reports Strong 2025 Results; Boston Scientific Acquires

Penumbra, Inc. announced robust financial results for the fourth quarter and full year 2025, alongside the disclosure of its proposed acquisition by Boston Scientific Corporation.

Summary

• Revenue for the fourth quarter of 2025 was $385.4 million, an increase of 22.1% (20.9% in constant currency) compared to the fourth quarter of 2024.
• Full year 2025 revenue reached $1,403.7 million, marking a 17.5% increase (16.9% in constant currency) over full year 2024.
• U.S. Thrombectomy revenue grew to $203.1 million in Q4 2025 (up 12.4%) and $771.5 million for the full year 2025 (up 19.3%).
• Global Embolization and Access product revenue increased to $130.7 million in Q4 2025 (up 37.0%, or 35.2% in constant currency) and $455.7 million for the full year 2025 (up 20.2%, or 19.4% in constant currency).
• Income from operations for Q4 2025 was $59.2 million, resulting in an operating margin of 15.4%. For the full year 2025, income from operations was $189.2 million, with an operating margin of 13.5%.
• Net income for Q4 2025 was $47.3 million (12.3% net income margin), and for the full year 2025, it was $177.7 million (12.7% net income margin).
• Adjusted EBITDA for Q4 2025 was $79.1 million (20.5% adjusted EBITDA margin), and for the full year 2025, it was $266.8 million (19.0% adjusted EBITDA margin).
• Gross profit for the full year 2025 was $942.4 million, or 67.1% of total revenue, an improvement from 63.2% in 2024, which included a one-time $33.4 million inventory impairment charge.
• The company will not provide financial guidance for the full year 2026 due to the proposed acquisition by Boston Scientific Corporation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by robust financial performance across key metrics and the strategic validation implied by the proposed acquisition by Boston Scientific, despite the lack of independent 2026 guidance.

Positives

• Strong revenue growth for Q4 2025 (22.1%) and Full Year 2025 (17.5%) demonstrates robust market demand and execution.
• Significant increase in income from operations for Full Year 2025 to $189.2 million, a substantial improvement from $9.3 million in 2024.
• Net income for Full Year 2025 rose dramatically to $177.7 million, up from $14.0 million in 2024.
• Adjusted EBITDA for Full Year 2025 grew to $266.8 million, compared to $165.2 million in 2024, indicating strong operational efficiency.
• Gross margin improved to 67.1% for the full year 2025, reflecting favorable product mix, improved productivity, and leveraging fixed costs on higher volume.
• Global Embolization and Access products showed exceptional growth, with Q4 revenue up 37.0% and full year revenue up 20.2%.
• U.S. revenue demonstrated strong performance, increasing 21.0% for the full year 2025.

Negatives

• International revenue growth for the full year 2025 was lower at 6.6% (4.2% in constant currency) compared to the robust U.S. growth of 21.0%.
• The company will not provide financial guidance for the full year 2026 due to the proposed acquisition, limiting forward visibility for independent analysis and investor projections.

Risks

• The pending acquisition by Boston Scientific Corporation may not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained.
• Potential adverse effects to the business during the pendency of the acquisition, such as employee departures or diversion of management's attention from the business.
• Failure to sustain or grow profitability or generate positive cash flows.
• Failure to effectively introduce and market new products.
• Delays in product introductions.
• Significant competition in the medical device market.
• Inability to further penetrate the current customer base, expand the user base, and increase the frequency of use of products by customers.
• Inability to achieve or maintain satisfactory pricing and margins.
• Manufacturing difficulties.
• Permanent write-downs or write-offs of inventory or other assets.
• Product defects or failures.
• Unfavorable outcomes in clinical trials.
• Inability to maintain the company culture as it grows.
• Fluctuations in foreign currency exchange rates.
• Potential adverse regulatory actions.
• The potential impact of any acquisitions, mergers, dispositions, joint ventures, or investments the company may make.

Future Outlook

The company will not be providing financial guidance for the full year 2026 due to the proposed acquisition by Boston Scientific Corporation.

Management Comments

• No specific notable quotes or paraphrased statements from company management were provided in the press release, beyond the standard corporate announcement of results and the acquisition.

Industry Context

StockSavvy.ai notes that Penumbra, as the world's leading thrombectomy company, operates in a high-growth segment of the medical device industry focused on critical interventions for conditions like ischemic stroke and venous thromboembolism. The proposed acquisition by Boston Scientific Corporation signifies a strategic consolidation within the medical technology sector, potentially enhancing Boston Scientific's portfolio in interventional therapies and validating Penumbra's innovative product pipeline and market leadership.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparison.

Stakeholder Impact

• Shareholders: Existing shareholders are likely to benefit from the acquisition premium offered by Boston Scientific, assuming the deal closes. Strong financial performance prior to acquisition enhances the company's value.
• Employees: Potential changes in corporate structure and culture due to the acquisition by Boston Scientific. The filing mentions 'employee departures or diversion of management's attention' as a risk during the pendency of the acquisition.
• Customers: Continued access to Penumbra's innovative thrombectomy and embolization products, potentially with broader reach and resources under Boston Scientific.
• Competitors: The acquisition consolidates market power, potentially increasing competition for other players in the thrombectomy and embolization markets.

Next Steps

• Completion of the proposed acquisition by Boston Scientific Corporation.
• Filing of the Annual Report on Form 10-K for the year ended December 31, 2025, on or before March 2, 2026.

Key Dates

Recommendation

Given the proposed acquisition by Boston Scientific Corporation, the investment thesis for Penumbra shifts from long-term growth potential as an independent entity to the certainty of the acquisition price. For existing shareholders, holding shares until the acquisition closes is typically recommended to realize the acquisition value, unless a higher offer is anticipated or immediate liquidity is preferred. For new investors, the upside is capped by the acquisition price, making it less attractive for a long-term growth investment.

Keywords

Penumbra, Boston Scientific, Acquisition, Financial Results, Thrombectomy, Embolization, Medical Devices, Q4 2025, Full Year 2025, Revenue, Net Income, EBITDA